Advisory Research’s Avita Medical RCEL Stock Holding History

Advisory Research’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,200	Closed	-$222K	–	453
2023 Q3	$222K	Sell	15,200 -31,894	-68%	-$540K	0.03%	408
2023 Q2	$801K	Buy	+47,094	New	+$691K	0.1%	230

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisory Research's RCEL Position: Q4 2023 in Review

Advisory Research sold out of Avita Medical (RCEL) in Q4 2023, closing a stake of 15,200 shares — an estimated $222K sold.

Advisory Research first reported a position in RCEL in Q2 2023 and held it in 2 quarters. The position peaked at $801K in Q2 2023. 84 funds tracked by Wall St. Rank hold RCEL as of Q4 2023.

Advisory Research reported no remaining Avita Medical position as of Q4 2023 after selling out during the quarter.
Advisory Research sold 15,200 Avita Medical shares in Q4 2023, an estimated $222K.
Advisory Research first reported a position in Avita Medical in Q2 2023 and held it in 2 quarters.
Advisory Research's Avita Medical position peaked at $801K in Q2 2023.
84 funds tracked by Wall St. Rank held Avita Medical as of Q4 2023.

Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.